<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975895</url>
  </required_header>
  <id_info>
    <org_study_id>031-16</org_study_id>
    <nct_id>NCT02975895</nct_id>
  </id_info>
  <brief_title>Outcome of Different IOLs in Patients With and Without Uveitis</brief_title>
  <official_title>Outcome With Hydrophobic and Hydrophilic Intraocular Lens in Patients With and Without Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual&#xD;
      acuity. In most cases it can be managed with surgery, removing the own lens and replacing it&#xD;
      with an artificial lens, intraocular lens (IOL). These lenses are made in different materials&#xD;
      with different properties.&#xD;
&#xD;
      Uveitis refers to an inflammation in the iris, ciliary body and choroid. Patients with this&#xD;
      disease have an increased risk of developing cataract due to the inflammation itself and&#xD;
      treatment with steroids. They also have an increased risk of complications during surgery and&#xD;
      postoperatively. In this group the selection of IOL might be of greater importance.&#xD;
&#xD;
      The aim of this prospective randomized controlled study is to compare the outcome of&#xD;
      hydrophobic and hydrophilic intraocular lenses in patients with and without uveitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory response</measure>
    <time_frame>Preoperatively and at seven occasions within two years postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after six months</measure>
    <time_frame>Six months (plus or minus 30 days) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after one year</measure>
    <time_frame>One year (plus or minus 30 days) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of posterior capsule opacification after two years</measure>
    <time_frame>Two years (plus or minus 2 months) postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity assessed in decimal using Snellen charts</measure>
    <time_frame>Preoperatively and at six occasions within two years postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Preoperatively and at seven occasions within two years postoperatively</time_frame>
    <description>Postoperative glaucoma or cystoid macular edema</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uveitis</condition>
  <condition>Cataract</condition>
  <condition>Inflammation</condition>
  <condition>Posterior Capsule Opacification</condition>
  <arm_group>
    <arm_group_label>Hydrophobic IOL: Vivinex (HOYA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraocular lens with hydrophobic properties: Vivinex (HOYA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrophilic IOL: INCISE (Bausch+Lomb)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrophobic IOL: Vivinex (HOYA)</intervention_name>
    <description>Patients requiring cataract surgery will be randomized to one of the two types of IOLs.</description>
    <arm_group_label>Hydrophobic IOL: Vivinex (HOYA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrophilic IOL: INCISE (Bausch+Lomb)</intervention_name>
    <description>Patients requiring cataract surgery will be randomized to one of the two types of IOLs.</description>
    <arm_group_label>Hydrophilic IOL: INCISE (Bausch+Lomb)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cataract requiring surgery&#xD;
&#xD;
          -  Ability to understand and sign consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive corneal scarring&#xD;
&#xD;
          -  Other eye surgery less than 3 months before inclusion&#xD;
&#xD;
          -  Unregulated glaucoma&#xD;
&#xD;
          -  Active uveitis (increased inflammation and treatment less than 3 months before&#xD;
             inclusion)&#xD;
&#xD;
          -  Intraoperative complications (capsular tear or vitreous loss)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeleine Zetterberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Västra Götalands regionen, Sahlgrenska University Hospital, Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

